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Background: Acute pancreatitis remains the most common major complication of endoscopic retrograde
cholangiopancreatography (ERCP). The pathogenesis of post-ERCP acute pancreatitis may be mediated by
oxygen-derived free radicals, which could be ameliorated by antioxidants. Antioxidant supplementation may
potentially prevent post-ERCP pancreatitis. We performed a meta-analysis of randomized controlled trials to
evaluate the effect of prophylactic antioxidant supplementation compared with control on the prevention of
post-ERCP pancreatitis.
Methods: PubMed and Embase databases were searched to identify relevant trials. A standardized Excel file was
used to extract data by two independent authors. Results were expressed as risk ratio (RR) with accompanying 95%
confidence interval (CI). The meta-analysis was performed with the fixed-effects model or random-effects model
according to heterogeneity.
Results: Eleven studies involving 3,010 patients met our inclusion criteria. Antioxidant supplementation did not
significantly decrease the incidence of post-ERCP pancreatitis (RR, 0.92; 95% CI, 0.65-1.32; P = 0.665). There was also
no statistical difference in the severity grades between the antioxidant group and control group.
Conclusions: Based on current evidence, antioxidant supplementation shows no beneficial effect on the incidence
and the severity of post-ERCP pancreatitis; thus, there is currently a lack of evidence to support using antioxidants
for the prevention of post-ERCP pancreatitis.
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Acute pancreatitis is the most common major and severe
complication of diagnostic and therapeutic ERCP, with the
reported incidence ranging from 1.8% to 7.2% in large
prospective series of nonselected patients [1-4]. The seve-
rity of post-ERCP pancreatitis can range from a mild
course with one or two days prolonged hospitalization and
full recovery to a devastating illness with hemorrhagic
pancreatitis, pancreatic necrosis, multiorgan failure, and* Correspondence: yinruixing@yahoo.com.cn
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reproduction in any medium, provided the oreven death [5]. Because post-ERCP pancreatitis is predic-
table and possibly preventable, numerous attempts have
been made to reduce the incidence and limit the severity
of this complication. However, most of them have largely
been disappointing.
Although the pathogenesis of post-ERCP pancreatitis is
not clearly understood, a number of studies have demon-
strated that an early step in the pathogenesis of acute
pancreatitis is capillary endothelial injury manifested by
an increase in capillary permeability [6,7]. Subsequent
researches have suggested that this capillary injury may be
mediated by oxygen-derived free radicals [8,9]. The mani-
festations of pancreatitis in experimental animal model can
be ameliorated by blocking the action of oxygen-derivedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the idea of antioxidant supplementation for the prevention
of post-ERCP pancreatitis seems rational and reasonable.
Two meta-analyses regarding allopurinol (an inhibitor
of oxygen-derived free-radicals) on the prevention of
post-ERCP pancreatitis have been published [13,14].
Both of them showed that allopurinol has no significant
effect on the prevention of post-ERCP pancreatitis.
However, one was only based on 4 trials and included
relatively modest sample sizes [13], and another included
half of the studies published in the abstract form, with-
out access to the full data [14]. Moreover, the role of
other antioxidants (such as N-acetylcysteine, β-carotene)
has not been well established. Recently, several relevant
randomized controlled trials (RCTs) regarding prophy-
lactic antioxidant supplementation in preventing post-
ERCP pancreatitis have been published. These reports
were well-performed RCTs and included an additional
more than 1,200 patients. We therefore undertook a
meta-analysis of randomized controlled trials to evaluate
the effect of prophylactic antioxidant supplementation
compared with control on the incidence and the severity
of post-ERCP pancreatitis.Methods
Literature search and inclusion criteria
Literature searches of the PubMed and Embase data-
bases (up to May 2012) were performed to identify RCTs
that compared antioxidant versus control for the preven-
tion of post-ERCP pancreatitis. The initial search terms
were antioxidant and pancreatitis, filtered by Humans
andRandomized Controlled Trial. In addition, the refe-
rence lists of identified studies were manually checked
to include other potentially eligible trials. This process
was performed iteratively until no additional articles
could be identified.
The following inclusive selection criteria were applied:
(i) study design: RCT; (ii) study population: adult
patients undergoing ERCP; (iii) intervention: antioxidant
supplementation (no matter what type and regimen
applied); (iv) comparison intervention: placebo or no
intervention; and (v) outcome measure: the incidence
and the severity of post-ERCP pancreatitis.Data extraction and outcome measure
Two authors (WJG and CYW) independently extracted
the following data from the selected studies: first author,
year of publication, number of patients (antioxidant/
control), patient characteristics, type of antioxidant, regi-
mens of antioxidant supplementation (route, dosage,
timing, frequency), study design, definition and severity
of post-ERCP pancreatitis, and outcome data. Extracted
data were entered into a standardized Excel file and werechecked by another author (RXY). Any disagreements
were resolved by discussion and consensus.
The outcome of interest was the incidence and the
severity of post-ERCP pancreatitis. The definition of post-
ERCP pancreatitis varied across studies, no standard defi-
nition was used in reported studies. In the majority of the
studies, the definition of post-ERCP pancreatitis and the
grading of its severity were based on the Cotton consensus
criteria [15].Quality assessment
The methodological quality of each trial was evaluated
using the Jadad scale [16]. The scale consists of three
items describing randomization (0–2 points), blinding
(0–2 points), and dropouts and withdrawals (0–1 points)
in the report of a randomized controlled trial. A score of
1 is given for each of the points described. A further point
is obtained where the method of randomization and/or
blinding is given and is appropriate; whereas it is inappro-
priate a point is deducted. The quality scale ranges from
0 to 5 points. Higher scores indicate better reporting. The
studies are said to be of low quality if the Jadad score
is ≤ 2 and high quality if the score is ≥ 3 [17].Statistical analyses
All outcomes were expressed as RR with 95% CI. The
Cochrane Q x2 test was used to detect heterogeneity of the
effects, significant heterogeneity was defined as a P value of
<0.05. A fixed-effects model or random-effects model was
used, depending on the absence or presence of heteroge-
neity. I2 statistic was estimated to describe the percentage
of the variability attributable to heterogeneity rather than
sampling error. Studies with an I2 statistic of < 25% are
considered to have no heterogeneity, those with an I2 statis-
tic of 25% to 50% are considered to have low heterogeneity,
those with an I2 statistic of 50% to 75% are considered to
have moderate heterogeneity, and those with an I2 statistic
of > 75% are considered to have high heterogeneity [18].
Whenever heterogeneity was present, sensitivity analyses
based on sample size, study quality, and omitting one study
in each turn were carried out to identify potential sources.
We also investigated the influence of a single study on the
overall pooled estimate by omitting one study in each turn.
Potential publication bias was assessed by visually
inspecting of the Begg funnel plot in which the RRs were
plotted against their SEs. The presence of publication
bias was also evaluated by using the Begg and Egger
tests [19,20]. A P value less than 0.05 was judged as
statistically significant, except where otherwise specified.
All statistical analyses were performed using STATA
version 11.0 (Stata Corporation, College Station, Texas,
USA).
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Study identification and selection
The PubMed and Embase search identified 42 and 25 po-
tential studies, respectively. A total of 67 RCTs were iden-
tified by the initial database search. Thirteen RCTs were
excluded because of duplicate studies and 43 RCTs were
excluded based on the titles and abstracts (reviews,
nonrandomized studies, or not relevant to our analysis).
The remaining 11 were then retrieved for full text review.
Finally, eleven RCTs met inclusion criteria and were
included in the analysis [21-31].
Study characteristics
The main characteristics of eleven RCTs included in this
meta-analysis are presented in Table 1 and the definition
and severity of post-ERCP pancreatitis of each included
trial are described in Table 2. These studies were pub-
lished between 1999 and 2011. The size of the RCT
ranged from 40 to 701 (total 3,010). Among the 11 studies
included here, all reported post-ERCP pancreatitis events
[21-31], 8 reported mild and moderate post-ERCP pan-
creatitis events [22-26,28,29,31], and 6 reported severe
post-ERCP pancreatitis events [22-24,26,28,29]. The
median Jadad score of the studies included was 3 (range
from 2 to 5).
All these patients were older than 18 years and sched-
uled for ERCP. The selected trials used different types of
antioxidant, including sodium selenite [21], allopurinol
[22,25,26,29-31], N-acetylcysteine [24,27], β-carotene [23],
and pentoxifylline [28]. These antioxidants were adminis-
tered orally or intravenously by different regimens and
formulations. Two studies used an intravenous route to
administer antioxidant [21,24], and the remaining nine
studies orally applied antioxidant during the perioperative
period [22,23,25-31]. Dosage, timing, and frequency of
these antioxidants are various.
The incidence of post-ERCP pancreatitis
The outcome data of each included trial are described in
Table 3. A total of 3,010 patients were included in the ten
trials comparing antioxidant with control for the prevention
of post-ERCP pancreatitis (1,484 in the antioxidant group
and 1,526 in the control group). Altogether, 266 patients
developed post-ERCP pancreatitis, 127 in the antioxidant
group and 139 in the control group. Antioxidant supple-
mentation were not associated with a significant reduction
in the incidence of post-ERCP pancreatitis (RR, 0.92; 95%
CI, 0.65-1.32; P = 0.665), with significant heterogeneity
among the studies (I2 = 44.7%; P = 0.054). Furthermore,
when trials were divided by the type of antioxidant, there
was also no significant decrease in post-ERCP pancreatitis
(RR for trials with allopurinol: 0.76; 95% CI: 0.41-1.42;
P = 0.396; and RR for trials with other antioxidants: 1.11;
95% CI: 0.74-1.66; P = 0.622) (Figure 1).Subsequently, we performed sensitivity analyses to ex-
plore potential source of heterogeneity. Exclusion of two
trials which had a modest sample size (N ≤ 100) yielded
similar results (RR 0.92; 95% CI 0.62-1.39; P = 0.702), with
moderate heterogeneity (I2 = 55.2%; P = 0.022) [21,31].
Exclusion of two studies with low quality (Jadad score ≤ 2)
did not change the pooled results substantially (RR 0.96;
95% CI 0.64-1.43; P = 0.823), yet heterogeneity was still
present (I2 = 53.6%; P = 0.028) [21,27]. Exclusion of one
study conducted by Katsinelos et al. changed the overall
estimate little (RR, 1.08; 95% CI, 0.85–1.37; P = 0.531), but
no evidence of heterogeneity was observed among the
remaining studies (I2 = 0%; P = 0.651) [25]. Further exclu-
sion of any single study also did not materially alter the
overall combined RR (data not shown).
The severity of post-ERCP pancreatitis
We also performed meta-analyses according to the grade
to explore the effect of antioxidant on the severity of post-
ERCP pancreatitis. Antioxidant supplementation had no
impact on mild post-ERCP pancreatitis (eight RCTs, RR
1.25, 95% CI 0.90-1.72; P = 0.183; I2 = 0%; heterogeneity
P = 0.776) (Figure 2), moderate post-ERCP pancreatitis
(eight RCTs, RR 0.80, 95% CI 0.53-1.22; P = 0.304;
I2 = 0.3%; heterogeneity P = 0.426) (Figure 3), or severe
post-ERCP pancreatitis (six RCTs, RR 0.71, 95% CI 0.30-
1.73; P = 0.455; I2 = 0%; heterogeneity P = 0.600)
(Figure 4).
Publication bias
Assessment of publication bias using Egger’s and Begg’s
tests showed that there was no potential publication bias
among the included trials (Egger’s test, P = 0. 443; Begg’s
test, P = 0.533, Figure 5).
Discussion
This is a further meta-analysis to evaluate the effect of
prophylactic antioxidant supplementation on the preven-
tion of post-ERCP pancreatitis. The present meta-analysis
of ten randomized controlled trials showed that antioxidant
supplementation did not significantly decrease the inci-
dence of post-ERCP pancreatitis. In addition, antioxidant
supplementation also showed no beneficial effect on the
severity of post-ERCP pancreatitis.
There have been two published meta-analyses of allo-
purinol (an inhibitor of oxygen-derived free-radicals) for
post-ERCP pancreatitis prevention [13,14]. Both of them
showed that the use of allopurinol was not associated with
reduction in the incidence of post-ERCP pancreatitis. Our
meta-analysis expands on these two earlier meta-analyses
to provide a better characterization of the evidence base
for antioxidant supplementation in preventing post-ERCP
pancreatitis. First, in our analysis, there are more enlarged
sample sizes than the previous analysis, giving greater
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ERCP = endoscopic retrograde cholangiopancreatography, NAC = N-acetylcysteine.
Gu et al. Nutrition Journal 2013, 12:23 Page 4 of 10
http://www.nutritionj.com/content/12/1/23
Table 2 Definition and severity of post-ERCP pancreatitis
Study Definition of post-ERCP pancreatitis Severity of post-ERCP pancreatitis
Wollschläger
et al. [21]
Presence of abdominal pain attributed to pancreatitis, in
association with a serum lipase or amylase level greater than 2




Presence of abdominal pain attributed to pancreatitis, together
with a need for an unplanned hospitalization or an extension of a
planned hospitalization by at least 2 d, and a serum amylase at
least 3 times above the upper limit of normal at 24 hours after
ERCP
Mild: symptoms lasting up to 3 d and pancreas normal on the CT
scan; moderate: requiring specific therapeutic measures for 4–10 d,
Balthazar’s grade B/C on CT; severe: local or systemic complications
for more than 10 d, Balthazar’s grade D/E on CT, or death
Lavy et al.
[23]
Presence of abdominal pain attributed to pancreatitis, in
association with elevated amylase levels at least 3 times higher
than the upper limit of normal
Mild: requiring 2–3 d of hospitalization; moderate: requiring 4–10
d of hospitalization; severe: requiring 10 d of hospitalization or
requiring surgical intervention or leading to death
Katsinelos
et al. [24]
Presence of abdominal pain attributed to pancreatitis, together
with a need for an unplanned hospitalization or an extension of a
planned hospitalization by at least 2 d, and a serum amylase at
least 3 times above the upper limit of normal at 24 hours after
ERCP
Mild: symptoms persisting for 3 d and a normal appearance of
the pancreas by US and/or CT; moderate: requirement for specific
therapeutic measures for 4 to 10 d (Balthazar’s grade B/C on CT);
severe: local or systemic complications for more than 10 d after
ERCP (Balthazar’s grade D/E) or death
Katsinelos
et al. [25]
Presence of abdominal pain attributed to pancreatitis, together
with a need for an unplanned hospitalization or an extension of a
planned hospitalization by at least 2 d, and a serum amylase at
least 3 times above the upper limit of normal at 24 hours after
ERCP
Mild: symptoms persisting for 3 d and a normal appearance of
the pancreas by US and/or CT; moderate: requirement for specific
therapeutic measures for 4 to 10 d (Balthazar’s grade B/C on CT);
severe: local or systemic complications for more than 10 d after
ERCP (Balthazar’s grade D/E) or death
Mosler et al.
[26]
New-onset or increased abdominal pain lasted for more than 24
h, caused an unplanned admission of an outpatient for more than
one night, or prolonged a planned admission of an inpatient, and
was associated with a serum amylase level increase of at least 3
times above normal, at approximately 18 hours (the next
morning) after ERCP
Mild: hospitalization lasted 2–3 d; moderate: hospitalization lasted
4–10 d; severe: hospitalization was prolonged for more than 1 0 d
or any of the following occurred: hemorrhagic pancreatitis,
pancreatic necrosis, pancreatic pseudocyst, or the need for
percutaneous drainage or surgery
Milewski
et al. [27]
Clinical features consistent with acute pancreatitis beginning after
ERCP and lasting for at least 24 h, associated with increase in




Presence of abdominal pain attributed to pancreatitis, together
with a need for an unplanned hospitalization or an extension of a
planned hospitalization by at least 2 d, and a serum amylase at
least 3 times above the upper limit of normal at 24 hours after
ERCP
Mild: clinical pancreatitis and serum amylase at least 3 times
higher than normal at more than 24 h after ERCP, requiring
admission or prolongation of planned admission for 2–3 d;
moderate: required hospitalization for 4–10 d; severe: required
hospitalization for more than 10 d, an intervention (percutaneous
drainage or surgery), or if a pseudocyst was diagnosed
Romagnuolo
et al. [29]
Presence of typical pancreatic pain (epigastric pain often radiating
into the back and associated with nausea and/or vomiting)
requiring medical attention, in association with a serum lipase or




Serum amylase was above 600 UI/L or 3 times above the normal
value and the patient had a sharp pain irradiating to the back and
nausea or vomiting
Ranson’s criteria (Parameter: At admission: age >55 y, WBC
count >16,000/uL, serum glucose level >11.1 mmol/L, SLDH/
ALT >350 IU/L, AST level >250 IU/L; During initial 48 h:
hematocrit: decrease of more than 0.10, BUN level: increase of
more than 5 mg/dL, calcium: <2 mmol/L, PaO2<60 mm Hg, base
deficit >4 mmol/L, fluid sequestration >6L): mild: two or fewer
grave signs; severe: more than six grave signs.
Abbasinazari
et al. [31]
NA Mild: amylase concentration at least 3 times above upper limit of
normal at more than 24 h after ERCP requiring admission for 2–3
d; moderate: admission for 4–10 d; severe: admission for more
than 10 d
ERCP = endoscopic retrograde cholangiopancreatography, NA = not available, AST = asparate aminotransferase, BUN = blood urea nitrogen, SLDH/ALT = serum
lactate dehydrogenate to alanine aminotransferase ratio, WBC = white blood cell.
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able of evaluating the effects of other antioxidants (such as
N-acetylcysteine, β-carotene, and selenite) on post-ERCP
pancreatitis prevention. Furthermore, we also were able to
evaluate the effect of antioxidant supplementation on the
severity of post-ERCP pancreatitis.Based on the previous meta-analysis, we furthermore
included other seven recent RCTs [21,23,25,27,28,30,31].
With the added statistical power of having 2,970 cases,
the present meta-analysis suggested that antioxidant
supplementation did not significantly decrease the inci-
dence of post-ERCP pancreatitis, which was in line with
Table 3 Outcome data of randomized controlled trials included in the meta-analysis















PEP stratified by severity
Mild Moderate Severe Mild Moderate Severe
Wollschläger et al. [21] 20 2 NA NA NA 20 3 NA NA NA
Budzyńska et al. [22] 99 12 9 2 1 101 8 5 3 0
Lavy et al. [23] 141 14 10 4 0 180 17 9 4 4
Katsinelos et al. [24] 124 15 8 7 0 125 12 7 5 0
Katsinelos et al. [25] 125 4 4 0 0 118 21 8 11 2
Mosler et al. [26] 355 46 28 16 2 346 42 24 16 2
Milewski et al. [27] 55 4 NA NA NA 51 6 NA NA NA
Kapetanos et al. [28] 158 9 6 1 2 162 5 4 0 1
Romagnuolo et al. [29] 293 16 8 6 2 293 12 4 6 2
Martinez et al. [30] 85 2 NA NA NA 85 8 NA NA NA
Abbasinazari et al. [31] 29 3 2 1 0 45 5 3 2 0
ERCP = endoscopic retrograde cholangiopancreatography, PEP = post-ERCP pancreatitis, NA = not available.
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single study and sensitivity analyses based on various ex-
clusion criteria did not materially alter the pooled
results, which adds robustness to our main finding. We
also assessed the effect of antioxidant supplementation
on the severity of post-ERCP pancreatitis, but failed to
find significant alteration.
There was significant heterogeneity between studies in
the overall analysis, which was not surprising given the
differences in characteristics of populations, antioxidantFigure 1 Forest plot showing the effect of antioxidant supplementatisupplementation, and definitions of pancreatitis. Our
sensitivity analyses suggest that one trial conducted by
Katsinelos et al. probably contributed to the heterogeneity
[25]. For this study, only 43 patients in the allopurinol
group underwent biliary sphincterotomy vs. 87 in the
placebo group; thus, there was significant difference in the
proportions of patients with biliary sphincterotomy
between the two groups (P < 0.001). Besides, exclusion of
the trial in our meta-analysis would not change our result;
antioxidant supplementation still did not significantlyon on the incidence of post-ERCP pancreatitis.
Figure 2 Forest plot showing the effect of antioxidant supplementation on the incidence of mild post-ERCP pancreatitis.
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patients; fixed-effects model: RR, 1.08; 95% CI, 0.85–1.37;
P = 0.531; data from nine trials) [21-23,25-31].
Furthermore, antioxidant therapy failed to prevent the
onset of post-ERCP pancreatitis in almost all trials. Only
one clinical trial in which 600 mg of allopurinol wasFigure 3 Forest plot showing the effect of antioxidant supplementatiadministered twice before ERCP showed a significant de-
crease in the rate of post-ERCP pancreatitis. The positive
result may be attributed to the high doses of allopurinol.
Wisner and Renner found that only high doses of allopu-
rinol were effective in preventing pancreatic edema and
an increase in serum amylase in caerulein-inducedon on the incidence of moderate post-ERCP pancreatitis.
Figure 4 Forest plot showing the effect of antioxidant supplementation on the incidence of severe post-ERCP pancreatitis.
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effective in fully suppressing xanthine oxidase, causing a
“leakage” of excessive radicals.
Most of the included RCTs did not reported adverse
effects of antioxidant during the study period. We found
that only 1 report indicated different adverse effects of N-
acetylcysteine. In the report [25], side effects most
commonly attributable to N-acetylcysteine (i.e., skin rash,
nausea, vomiting, and diarrhea) were observed with
increased frequency in the N-acetylcysteine group (25% vs.
3.2%, N-acetylcysteine and placebo groups, respectively;
P < 0.001).Figure 5 Tests for publication bias for RR of the incidence the incidenThe results of this meta-analysis must be interpreted
cautiously in light of the strengths and limitations of the
included trials. A major strength of this study is that all
the included original studies used a randomized controlled
design and most of them were well-performed, high-
quality (Jadad score ≥ 3 in nine trials). In addition, with
the enlarged sample size, we have enhanced statistical
power to provide more precise and reliable effect esti-
mates. Although the present analysis represents a complete
summary of the current available evidence for antioxidant
supplementation in preventing post-ERCP pancreatitis, it
also serves to highlight limitations that remain. Onece of post-ERCP pancreatitis.
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and the lack of standard regimens of antioxidant applied in
the randomized trials to date. These factors may result in
the heterogeneity and have potential impact on our results.
Furthermore, the variety of criteria was used to define pan-
creatitis. In the majority of the studies, the definition of
post-ERCP pancreatitis and the grading of its severity were
based on the Cotton consensus criteria [15]. Finally, explor-
ation of the impact of antioxidant supplementation on other
clinically meaningful endpoints including hyperamylasemia
and length of the hospital stay has not been sufficient
because of sparse and inconsistent reporting across the
reviewed studies.
Conclusions
In conclusion, the results suggest that antioxidant supple-
mentation shows no beneficial effect on the incidence and
the severity of post-ERCP pancreatitis. There is currently a
lack of evidence to support using antioxidants for the pre-
vention of post-ERCP pancreatitis.
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